FDA — authorised 26 February 1982
- Application: NDA018660
- Marketing authorisation holder: BAXTER HLTHCARE
- Local brand name: TRAVAMULSION 10%
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Intralipid 20% in United States
FDA authorised Intralipid 20% on 26 February 1982
Marketing authorisations
FDA — authorised 29 June 1983
- Application: NDA018465
- Marketing authorisation holder: ALPHA THERA
- Local brand name: SOYACAL 10%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 19 August 1985
- Application: NDA018758
- Marketing authorisation holder: BAXTER HLTHCARE
- Local brand name: TRAVAMULSION 20%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 28 May 1993
- Application: NDA019531
- Marketing authorisation holder: B BRAUN
- Local brand name: NUTRILIPID 10%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 December 1993
- Application: NDA019942
- Marketing authorisation holder: FRESENIUS
- Local brand name: INTRALIPID 30%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 13 January 1998
- Application: NDA020181
- Marketing authorisation holder: HOSPIRA
- Local brand name: LIPOSYN III 30%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
Intralipid 20% in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Intralipid 20% approved in United States?
Yes. FDA authorised it on 26 February 1982; FDA authorised it on 29 June 1983; FDA authorised it on 19 August 1985.
Who is the marketing authorisation holder for Intralipid 20% in United States?
BAXTER HLTHCARE holds the US marketing authorisation.